血液检测市场机会、成长要素、产业趋势分析及2026年至2035年预测

2025 年全球血液检测市场价值 895 亿美元，预计到 2035 年将以 7.4% 的复合年增长率成长，达到 1,798 亿美元。

慢性病和感染疾病的上升、诊断技术的持续创新以及就地检验设施的快速成长是推动市场扩张的主要因素。全球医疗费用支出的成长进一步增强了市场势头，使医院和实验室能够投资于自动化系统、先进的分析仪器和高品质的耗材，从而提高诊断准确性和工作流程效率。政府主导的医疗改革、优惠的报销方案以及扩大的保险覆盖范围也促进了常规诊断筛检和疾病早期发现。在发展中地区，基础设施建设和协作医疗模式的推进正在加速现代诊断服务的普及。血液检测在临床决策中发挥着至关重要的作用；透过测量细胞和生化参数，对血液样本进行检查室分析，有助于疾病诊断、健康评估、治疗后续观察和器官功能评估。

预计到2025年，血液常规检查市场规模将达到132亿美元，占全球市场份额的14.7%。血液常规检查检测因其能够提供全面的健康讯息，仍然是应用最广泛的诊断程序之一。透过评估各种血液成分，该检测有助于发现血液学异常和全身性疾病。其在预防医学、治疗前评估和持续健康监测中的常规应用，确保了医院、独立实验室和分散式检查机构的持续需求。全血球计数检测的临床意义和广泛效用使其成为全球血液检测产业的基础要素。

预计到2025年，试剂和试剂盒市场规模将达到527亿美元，占整个市场的58.8%。试剂和试剂盒是诊断检测的基础，包含用于准确检体分析所需的特殊化学成分和即用型组件。这些产品广泛应用于多个诊断领域，确保生物标记和疾病指标的可靠识别。它们在各种检测程序中的重复使用为製造商提供了稳定的收入来源。对能够提供精确且可重复结果的标准化、高品质试剂的需求持续推动着该细分市场的成长，并巩固了其在检查室操作中的关键作用。

预计到2025年，美国血液检测市场规模将达253亿美元。这主要得益于慢性病的高发生率，而慢性病需要定期进行诊断监测。持续的疾病监测、早期疗育策略和长期治疗管理都高度依赖检查室血液分析。为了满足日益增长的诊断需求，医疗机构正越来越多地采用自动化、高通量检测平台，旨在提高效率、准确性和结果报告速度。对先进检测技术的投资依然强劲，进一步巩固了美国在全球血液检测市场的地位。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 慢性病和感染疾病的增加加重了负担
    • 血液检测设备的技术进步
    • 即时检测中心数量激增
    • 医疗费用支出增加和有利政策
  • 产业潜在风险与挑战
    • 血液检测设备高成本
    • 与血液检测过程相关的错误
  • 市场机会
    • 家庭和远端测试解决方案
• 成长潜力分析
• 监理情势
• 技术进步
  • 当前技术趋势
  • 新兴技术
• 2024年价格分析
• 未来市场趋势
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
• 公司矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 合作伙伴关係和合资企业
  • 新产品发布
  • 扩张计划

第五章 市场估计与预测：依测试类型划分，2022-2035年

• 血液常规检查
• 血糖测试
• 心臟检查
• 传染病筛检
• 肾功能检查 - 肾功能指标
• 胆固醇检测 - 血脂分析
• 癌症筛检
• 尿液检查
• 抗体检测 - 类风湿因子
• 其他类型的测试

第六章 市场估算与预测：依产品划分，2022-2035年

• 试剂和试剂盒
• 装置
• 软体

第七章 市场估计与预测：依方法划分，2022-2035年

• 自动化
• 手动的

第八章 市场估算与预测：依最终用途划分，2022-2035年

• 医院
• 病理检查室
• 血库
• 诊断中心
• 其他最终用户

第九章 市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿拉伯聯合大公国

第十章：公司简介

• Danaher
• F Hoffmann-La Roche Ltd.
• Abbott Laboratories
• BioMerieux SA
• Grifols
• Becton, Dickinson and Company
• Bio-Rad Laboratories Inc.
• Siemens Healthineers
• Sinocare Inc.
• Trinity Biotech
• Thermo Fisher Scientific Inc.
• B. Braun Melsungen AG

The Global Blood Testing Market was valued at USD 89.5 billion in 2025 and is estimated to grow at a CAGR of 7.4% to reach USD 179.8 billion by 2035.

Market expansion is fueled by the rising incidence of chronic and infectious diseases, continuous innovation in diagnostic technologies, and the rapid growth of point-of-care testing facilities. Increasing healthcare expenditure worldwide is further strengthening market momentum, enabling hospitals and laboratories to invest in automated systems, advanced analyzers, and high-quality consumables that enhance diagnostic precision and workflow efficiency. Government-backed healthcare reforms, favorable reimbursement structures, and expanded insurance coverage are also encouraging routine diagnostic screening and early disease detection. In developing regions, infrastructure upgrades and collaborative healthcare models are accelerating access to modern diagnostic services. Blood testing plays a critical role in clinical decision-making, as laboratory analysis of blood samples supports disease diagnosis, health assessment, therapeutic monitoring, and evaluation of organ function through the measurement of cellular and biochemical parameters.

The complete blood count segment generated USD 13.2 billion in 2025 and accounted for 14.7% share. Complete blood count testing remains one of the most widely performed diagnostic procedures due to its ability to provide comprehensive information about overall health status. By evaluating various blood components, this test supports the detection of hematological abnormalities and systemic conditions. Its routine application in preventive care, pre-procedural assessments, and ongoing health monitoring ensures sustained demand across hospitals, independent laboratories, and decentralized testing environments. The consistent clinical relevance and broad utility of complete blood count testing have positioned it as a foundational component of the global blood testing industry.

The reagents and kits segment reached USD 52.7 billion in 2025, representing a substantial 58.8% share. Reagents and kits form the backbone of diagnostic testing, as they contain specialized chemical formulations and ready-to-use components required for accurate sample analysis. These products are utilized across multiple diagnostic disciplines, ensuring reliable identification of biomarkers and disease indicators. Their recurring consumption in every testing procedure drives consistent revenue generation for manufacturers. The need for standardized, high-quality reagents that deliver precise and reproducible results continues to propel segment growth, reinforcing their indispensable role in laboratory operations.

U.S. Blood Testing Market reached USD 25.3 billion in 2025, supported by a high prevalence of chronic health conditions requiring regular diagnostic monitoring. Continuous disease surveillance, early intervention strategies, and long-term treatment management depend heavily on laboratory-based blood analysis. To address rising diagnostic volumes, healthcare providers are adopting automated and high-throughput testing platforms designed to improve efficiency, accuracy, and turnaround times. Investment in advanced laboratory technologies remains strong, further strengthening the country's position within the global blood testing landscape.

Key participants operating in the Global Blood Testing Market include Abbott Laboratories, Danaher, Siemens Healthineers, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Thermo Fisher Scientific Inc, Becton, Dickinson and Company, Grifols, Trinity Biotech, Sinocare Inc, BioMerieux SA, and B. Braun Melsungen AG. Companies in the blood testing market are reinforcing their competitive edge through strategic product innovation and portfolio expansion. Continuous investment in research and development enables the introduction of advanced diagnostic platforms, automated analyzers, and high-sensitivity reagents that improve accuracy and efficiency. Many organizations are forming strategic collaborations and distribution partnerships to expand geographic reach and strengthen supply chain capabilities. Firms are also focusing on regulatory approvals and quality certifications to enhance credibility and market acceptance. Expansion into emerging economies through localized manufacturing and service networks is another key growth strategy.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Test type trends
  • 2.2.3 Product trends
  • 2.2.4 Method trends
  • 2.2.5 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing burden of chronic and infectious diseases
    • 3.2.1.2 Technological advancements in blood testing devices
    • 3.2.1.3 Burgeoning number of point-of-care (POC) testing centers
    • 3.2.1.4 Increasing healthcare expenditure and favorable policies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of blood testing devices
    • 3.2.2.2 Errors associated with blood testing process
  • 3.2.3 Market opportunities
    • 3.2.3.1 Home-based and remote testing solutions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technological advancements
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis, 2024
• 3.7 Future market trends
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Test type, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Complete blood count test
• 5.3 Blood glucose test
• 5.4 Heart test
• 5.5 Infectious disease screening
• 5.6 Kidney test- renal profile
• 5.7 Cholesterol test- lipid profile test
• 5.8 Cancer test
• 5.9 Urine test
• 5.10 Antibodies test - rheumatoid factor
• 5.11 Other test types

Chapter 6 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Reagents and kits
• 6.3 Instruments
• 6.4 Software

Chapter 7 Market Estimates and Forecast, By Method, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Automated
• 7.3 Manual

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Pathology labs
• 8.4 Blood banks
• 8.5 Diagnostic centers
• 8.6 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Danaher
• 10.2 F Hoffmann-La Roche Ltd.
• 10.3 Abbott Laboratories
• 10.4 BioMerieux SA
• 10.5 Grifols
• 10.6 Becton, Dickinson and Company
• 10.7 Bio-Rad Laboratories Inc.
• 10.8 Siemens Healthineers
• 10.9 Sinocare Inc.
• 10.10 Trinity Biotech
• 10.11 Thermo Fisher Scientific Inc.
• 10.12 B. Braun Melsungen AG